As much as you don't want to hear it the company is not focusing on the TPIV vaccines. They already shut down the company sponsored trial in ovarian. They will not provide the payoff that MultiTAA has the potential to provide. It's unfortunate but it is what it is and to be honest it's probably for the best right now to use their financial resources for MultiTAA. Not the peptide vaccines. The Mayo trials should continue and if anything comes from those then maybe they further explore the vaccines but if MultiTAA pans out I would assume the peptide vaccines will never see the light of day.
News 
Market Data 
Discover 
